OS Therapies completes warrant inducement, raises $3.8M; extends funding into 2027

OS Therapies Inc

Raised ~$3.78M gross from exercise of 3,373,043 existing warrants at $1.12; issued new warrants at $3.00 exercise price.
New warrants have forced exercise provision if stock trades above $9.00 for 20 consecutive days; could provide over $20M.
Proceeds to accelerate OST-HER2 commercial launch for pulmonary metastatic osteosarcoma; company funded into 2027.
Removal of old $1.12 warrants reduces potential short selling activity, per CEO Paul Romness.
Offering completed with all remaining holders; substantially similar to prior inducement offers in June/July 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.